External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing
Top Cited Papers
Open Access
- 15 June 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (12) , 4328-4337
- https://doi.org/10.1158/0008-5472.can-04-0073
Abstract
Local radiation is an established therapy for human tumors. Radiation also has been shown to alter the phenotype of target tissue, including gene products that may make tumor cells more susceptible to T-cell-mediated immune attack. We demonstrate a biological synergy between local radiation of tumor and active vaccine therapy. The model used consisted of mice transgenic for human carcinoembryonic antigen (CEA) and a murine carcinoma cell line transfected with CEA. The vaccine regimen consisted of a prime and boost strategy using vaccinia and avipox recombinants expressing CEA and three T-cell costimulatory molecules. One dose of 8-Gy radiation to tumor induced up-regulation of the death receptor Fas in situ for up to 11 days. However, neither radiation at this dose nor vaccine therapy was capable of inhibiting growth of 8-day established tumor. When vaccine therapy and local radiation of tumor were used in combination, dramatic and significant cures were achieved. This was mediated by the engagement of the Fas/Fas ligand pathway because Ag-bearing tumor cells expressing dominant-negative Fas were not susceptible to this combination therapy. Following the combination of vaccine and local radiation, tumors demonstrated a massive infiltration of T cells not seen with either modality alone. Mice cured of tumors demonstrated CD4+ and CD8+ T-cell responses specific for CEA but also revealed the induction of high levels of T-cell responses to two other antigens (gp70 and p53) overexpressed in tumor, indicating the presence of a consequential antigen cascade. Thus, these studies demonstrate a new paradigm for the use of local tumor irradiation in combination with active specific vaccine therapy to elicit durable antitumor responses of established tumors.Keywords
This publication has 36 references indexed in Scilit:
- Epigenetic changes in tumor Fas levels determine immune escape and response to therapyCancer Cell, 2002
- Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8 + cytotoxic T lymphocytesCancer Immunology, Immunotherapy, 2001
- MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitopeEuropean Journal of Immunology, 1999
- Cytotoxicity of Fas ligand against lymphoma cells with radiation-induced Fas antigen.International Journal of Molecular Medicine, 1998
- A wild‐type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cellsEuropean Journal of Immunology, 1996
- The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.Proceedings of the National Academy of Sciences, 1996
- Role of Fas-mediated cell death in the regulation of immune responsesCurrent Opinion in Immunology, 1996
- Mechanisms of Lysis by Cytotoxic T CellsCritical Reviews in Immunology, 1995
- Cytotoxic Lymphocytes: Two ways to kill target cellsCurrent Biology, 1994
- RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1992